Novavax

829 articles with Novavax

• Novavax to Participate in 2022 Jefferies London Healthcare Conference

  11/14/2022

  Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced that it will participate in the Jefferies London Healthcare Conference.

• Novavax Nuvaxovid™ COVID-19 Vaccine▼ Authorized in the United Kingdom for Use as a Booster in Adults

  11/9/2022

  Novavax, Inc. (Nasdaq: NVAX) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (U.K.) has expanded the conditional marketing authorization (CMA)i for Nuvaxovid™.

• Novavax Reports Third Quarter 2022 Financial Results and Operational Highlights

  11/8/2022

  Novavax, Inc. (NASDAQ: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highlights for the third quarter ended September 30, 2022.

• Novavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster

  11/8/2022

  Novavax, Inc. today announced topline results from its Phase 3 Boosting Trial for the SARS-CoV-2 rS Variant Vaccines (COVID-19) showing that the Company's BA.1 vaccine candidate (NVX-CoV2515) met the primary strain-change endpoint.

• Novavax Appoints Rick Rodgers to Board of Directors

  11/1/2022

  Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced the appointment of Richard Rodgers, MBA to its board as an independent director.

• Novavax to Host Conference Call to Discuss Third Quarter 2022 Financial Results and Operational Highlights on November 8, 2022

  11/1/2022

  Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced it will report its third quarter 2022 financial results and operational highlights on Tuesday, November 8, 2022, following the close of U.S. financial markets.

• Novavax Showcases Data from Expanding Vaccine Portfolio at IDWeek 2022

  10/20/2022

  Novavax, Inc. (Nasdaq: NVAX) will present new data from the Phase 3 PREVENT-19 trial evaluating its protein-based COVID-19 vaccine (NVX-CoV2373) as a booster in adults, including a breakdown by age and by booster dose interval (8 and 11 months) at IDWeek 2022, October 20 to 22, 2022.

• U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster for Adults

  10/19/2022

  Novavax, Inc. today announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) has received emergency use authorization (EUA) from the U.S. Food and Drug Administration.

• Novavax COVID-19-Influenza Combination Vaccine Candidate Induced Antibody and T-Cell Responses Against SARS-CoV-2 and Homologous and Heterologous Influenza Strains

  10/13/2022

  Novavax, Inc. today announced positive results from the Phase 1/2 clinical trial of its COVID-19-Influenza Combination (CIC) vaccine candidate. 

• Novavax Prototype COVID-19 Vaccine Data Support Homologous and Heterologous Boosting and Suggest Benefit Against Variants

  10/12/2022

  Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today presented data from the Phase 3 PREVENT-19 trial and Study 307 (Lot Consistency) at the World Vaccine Congress Europe 2022.

• Novavax to Share New Data from Growing Vaccine Portfolio at World Vaccine Congress Europe 2022

  10/10/2022

  Novavax, Inc. will present new safety and immunogenicity data from the first Phase 1/2 COVID-Influenza Combination (CIC) dose-finding trial evaluating its CIC vaccine candidate at the World Vaccine Congress (WVC) Europe, October 11 to 14, 2022.

• Novavax Makes One Million Doses of Nuvaxovid™ Available for Use in the United Kingdom

  9/27/2022

  Novavax, Inc. today announced that an initial one million doses of Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine are now available for use in the United Kingdom (U.K.).

• Novavax Nuvaxovid™ COVID-19 Vaccine Receives Expanded Emergency Use Authorization in Taiwan for Use in Adolescents Aged 12 Through 17

  9/16/2022

  Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Taiwan Food and Drug Administration (TFDA) has granted expanded emergency use authorization (EUA) for Nuvaxovid.

• Novavax Nuvaxovid™ COVID-19 Vaccine Now Available in Israel for Individuals Aged 12 and Older

  9/16/2022

  Novavax, Inc. today announced that the Israel Ministry of Health has granted an import and use permit which provides individuals aged 12 and older access to the Nuvaxovid.

• Novavax and Serum Institute of India Announce Full Product Registration in South Africa of Novavax COVID-19 Vaccine as a Primary Series for Adults Aged 18 and Older

  9/13/2022

  Novavax, Inc. (Nasdaq: NVAX) today announced that the South African Health Products Regulatory Authority has granted full product registration with conditions for Novavax' protein-based vaccine, NVX-CoV2373, as a two-dose primary series for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adults aged 18 and older.

• Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the European Union for Use as a Booster for Adults Aged 18 and Older

  9/12/2022

  Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the European Commission (EC) has approved the expanded conditional marketing authorization (CMA) of Nuvaxovid™ .

• Novavax to Participate in Upcoming September 2022 Conferences

  9/7/2022

  Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced that it will participate in two upcoming investor conferences.

• Swissmedic Authorizes Novavax Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 Through 17 and as a Booster in Adults Aged 18 and Older

  9/2/2022

  Novavax, Inc. (Nasdaq: NVAX), today announced that Swissmedic, the Swiss Agency for Therapeutic Products, has expanded its temporary authorization of Nuvaxovid™ (NVX-CoV2373).

• Novavax Nuvaxovid™ COVID-19 Vaccine Recommended by CHMP for Expanded Conditional Marketing Authorization in the European Union as a Booster for Adults Aged 18 and Older

  9/1/2022

  Novavax, Inc. (Nasdaq: NVAX), today announced that Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine has been recommended for expanded conditional marketing authorization (CMA) in the European Union (EU) as a homologous and heterologous booster for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for adults aged 18 and older.

• Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the United Kingdom for Use in Adolescents Aged 12 Through 17

  8/26/2022

  Novavax, Inc. (Nasdaq: NVAX), today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) has granted expanded conditional marketing authorization (CMA) for Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine.